Dalteparin Other names: Dalteparin sodium

Therapeutic indications

Dalteparin is indicated for:

Peri-operative and post-operative surgical thromboprophylaxis

Population group: only adults (18 years old or older)

at least one of
Anticoagulant prophylaxis
Prevention of deep vein thrombosis
and additionally Surgical procedure

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prolonged thromboprophylaxis in hip replacement surgery

Population group: only adults (18 years old or older)

at least one of
Anticoagulant prophylaxis
Prevention of deep vein thrombosis
and additionally at least one of
Limb operation
Skeletal fixation

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prophylaxis of venous thromboembolism in medical patients

Population group: only adults (18 years old or older)

at least one of
Anticoagulant prophylaxis
Prevention of deep vein thrombosis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prevention of venous thromboembolism (VTE) in patients with solid tumours

Population group: only adults (18 years old or older)

Extended treatment of symptomatic venous thromboembolism (VTE) and prevention of its recurrence.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Venous thromboembolism (VTE), deep vein thrombosis (DVT), pulmonary embolism (PE)

Population group: only adults (18 years old or older)

Treatment of venous thromboembolism (VTE) presenting clinically as deep vein thrombosis (DVT), pulmonary embolism (PE) or both.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Unstable angina, non-Q wave myocardial infarction

Population group: only adults (18 years old or older)

Unstable angina and non-Q wave myocardial infarction (unstable coronary artery disease-UCAD), administered concurrently with aspirin.

Patients needing treatment beyond 8 days, while awaiting angiography/revascularisation, should receive a fixed dose of either 5,000 IU (women <80 kg and men <70 kg) or 7,500 IU (women ≥80 kg and men ≥70 kg) 12 hourly. Treatment is recommended to be given until the day of the revascularisation procedure (PTCA or CA BG) but not for more than 45 days.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Dalteparin is contraindicated in the following cases:

Heparin induced thrombocytopenia, acute gastroduodenal ulcer, haemorrhage, coagulation disorders

at least one of
Heparin-induced thrombocytopenia
Acute peptic ulcer
Cerebral hemorrhage
Blood coagulation disorder
Bleeding
Malignant endocarditis

Local anaesthesia, regional anaesthesia

at least one of
Local anaesthesia
Regional anesthesia

Hypersensitivity to dalteparin

Dalteparin allergy

Acute bacterial endocarditis, slow endocarditis

at least one of
Acute bacterial endocarditis
Subacute bacterial endocarditis

Operations on the central nervous system, eyes and ears

at least one of
Operation on brain
Procedure on spinal cord
Surgical procedure on eye region
Operation on the ear

Disseminated intravascular coagulation (DIC)

Disseminated intravascular coagulation

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2020: FRAGMIN 7.500 IU Solution for injection
Summary of Product Characteristics (SPC) 2020: FRAGMIN 2.500 IU Solution for injection
Summary of Product Characteristics (SPC) 2020: FRAGMIN 10.000 IU Solution for injection
Summary of Product Characteristics (SPC) 2020: FRAGMIN 12.500 IU Solution for injection
Summary of Product Characteristics (SPC) 2020: FRAGMIN 100.000 IU Solution for injection
Summary of Product Characteristics (SPC) 2020: FRAGMIN 5.000 IU Solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈